Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy

Area of Science:

• Immunology
• Oncology
• Epigenetics

Background:

• Allogeneic stem cell transplantation (SCT) shows promise for solid tumors but is limited by graft-versus-host disease (GVHD).
• Minor histocompatibility antigens (mHags), such as HA-1, offer potential targets for cancer immunotherapy due to restricted expression.
• A significant subset of solid tumors (30-40%) are HA-1 negative (HA-1(neg)), limiting HA-1-specific immunotherapy efficacy.

Purpose of the Study:

• To investigate the transcriptional regulation of HA-1 gene expression in solid tumors.
• To identify mechanisms responsible for the absence of HA-1 expression in certain cancers.
• To explore strategies for overcoming HA-1 negativity in tumors for enhanced immunotherapy.

Main Methods:

• Analysis of HA-1 promoter methylation in solid tumor cell lines and primary cancers.
• Treatment of HA-1(neg) tumor cells with the hypomethylating agent 5-aza-2'-deoxycytidine.
• Treatment with the histone deacetylation inhibitor trichostatin A.
• Assessment of HA-1 expression and sensitization to HA-1-specific T cells.

Main Results:

• DNA hypermethylation in the HA-1 promoter region strongly correlates with absent HA-1 gene expression in solid tumor cell lines and primary tumors.
• 5-aza-2'-deoxycytidine treatment induced HA-1 expression specifically in HA-1(neg) tumor cells, sensitizing them to HA-1-specific cytotoxic T lymphocytes.
• Trichostatin A induced HA-1 expression in some HA-1(neg) tumor cells and also in normal nonhematopoietic cells.

Conclusions:

• Promoter hypermethylation is a key mechanism regulating HA-1 gene expression in tumors.
• Hypomethylating drugs represent a promising strategy to re-express HA-1 in negative tumors.
• This approach could broaden the application of HA-1-based immunotherapy in solid tumors post-allogeneic SCT, potentially reducing GVHD risk.